Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
Holding KURA?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.57Last Year’s EPS
-$0.55Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -49.30%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials for ziftomenib, financial stability, and regulatory achievements, but also noted increased expenses and some clinical challenges.Company Guidance
During the Kura Oncology Q3 2024 earnings call, the company's leadership provided detailed guidance on their ongoing and upcoming clinical trials, financial status, and strategic direction. The menin inhibitor program, particularly the ziftomenib trials, was highlighted, with promising data from the KOMET-007 trial showcasing a robust safety and efficacy profile in both relapsed/refractory and frontline acute myeloid leukemia (AML) settings. The Phase Ia study demonstrated promising activity with no dose-limiting toxicities (DLTs) or QTc prolongation, and a 12% occurrence of on-target differentiation syndrome, which was manageable. The Phase Ib expansion at 600 milligrams is expected to enroll 20 patients per cohort, with preliminary data anticipated in 2025. Financially, Kura reported a Q3 2024 net loss of $54.4 million, up from $38.6 million in Q3 2023, attributed to increased R&D expenses, with $455.3 million in cash and investments sufficient to fund operations into 2027. Additionally, the company plans to advance next-generation menin inhibitors for diabetes and explore other therapeutic areas.Robust Clinical Data for Menin Inhibitor Program
Kura Oncology continues to generate clinical data supporting ziftomenib in treating menin-dependent AML, showing a durable safety and efficacy profile in combination with standard care therapies.
Encouraging Results from KOMET-007 Trial
In the KOMET-007 trial, 100% of NPM1-mutant AML patients and 84% of KMT2A rearranged patients remained on study one year after initiation, with no differentiation syndrome reported at lower doses.
Breakthrough Therapy Designation for Ziftomenib
Ziftomenib is the first investigational therapy to receive breakthrough therapy designation for relapsed and refractory NPM1-mutant AML by the FDA.
Strong Financial Position
As of September 30, 2024, Kura Oncology had $455.3 million in cash and investments, expected to fund operations into 2027.
---
KURA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KURA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $17.77 | $17.68 | -0.51% |
| Aug 08, 2024 | $19.12 | $18.97 | -0.78% |
| May 02, 2024 | $20.59 | $20.63 | +0.19% |
| Feb 27, 2024 | $21.76 | $21.38 | -1.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Kura Oncology (KURA) report earnings?
Kura Oncology (KURA) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Kura Oncology (KURA) earnings time?
Kura Oncology (KURA) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KURA EPS forecast?
KURA EPS forecast for the fiscal quarter 2024 (Q4) is -$0.57.
---